Rechallenging with anthracyclines and taxanes in metastatic breast cancer

Palmieri, Carlo; Krell, Jonathan; James, Colin R.; Harper‐Wynne, Catherine; Misra, Vivek; Cleator, Susan; Miles, David

doi:10.1038/nrclinonc.2010.122

Cited by 58 publications

(44 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, several epothilones have been developed, which bind a similar site on tubulin but differ from the taxanes in specific binding characteristics, potency, and cross-resistance (28)(29)(30). A number of microtubule-stabilizing drug regimens are under investigation for refractory metastatic disease (31,32). The current report describes a new drug related to the taxanes, TPI-287.…”

Section: Discussionmentioning

confidence: 99%

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

Fitzgerald

Emerson

Qian

et al. 2012

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Brain metastases of breast and other cancers remain resistant to chemotherapeutic regimens that are effective systemically, in part due to the blood-brain barrier. We report that TPI-287, a new microtubule-stabilizing agent, displays in vitro cytotoxic activity similar to taxanes and epothilones. Unlike the taxanes, TPI-287 is permeable through the blood-brain barrier. Brain-to-plasma ratios of TPI-287 after a single injection typically exceeded one and were as high as 63.8 in the rat and 14.1 in the mouse. A brain-tropic derivative of the MDA-MB-231 triple-negative breast cancer cell line, 231-BR, was used to test whether TPI-287 may be efficacious at preventing or treating brain metastases. TPI-287 had growth inhibitory effects comparable with paclitaxel when 231-BR tumor cells were injected into the mammary fat pad. Brain metastatic colonization was determined by intracardiac injection of 231-BR cells, with treatment beginning on day 3 to 4 postinjection, culminating in a histologic count of brain metastases in brains necropsied days 25 to 28 postinjection. In this assay, paclitaxel, ixabepilone, and nab paclitaxel did not have significant inhibitory activity. TPI-287 was ineffective in the same assay using a 6 mg/kg every week schedule; however an 18 mg/kg dose delivered on days 3, 7, and 11 significantly reduced the outgrowth of brain metastases (55% reduction, P ¼ 0.028) and reduced proliferation in brain metastases (16% reduction, P ¼ 0.008). When TPI-287 treatment was delayed until days 18, 22, and 26 postinjection, efficacy was reduced (17% reduction, not significant). These data suggest that TPI-287 may have efficacy when administered early in the course of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

Fitzgerald

Emerson

Qian

et al. 2012

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Despite current lack of standard of care, a considerable proportion of these women receives multiple lines of treatment for metastatic disease, including taxane rechallenge, according to previous efficacy and tolerance, with results that justify this practice [Roché and Vahdat, 2011;Planchat et al 2011;Palumbo et al 2013;Cardoso et al 2014]. However, very few data are available outlining outcomes after this pragmatic approach in MBC [Palmieri et al 2010;Toulmonde et al 2012;Andreupoulou and Sparano, 2013]. In clinical practice, the introduction of liposomal anthracyclines offers an opportunity for anthracycline rechallange in MBC, whereas taxane rechallange may be possible by selecting a different taxane, using an alternative regimen of the same agent or selecting paclitaxel albumin [Palmieri et al 2010].…”

Section: Clinical Development Of Nab-paclitaxel In Breast Cancer Patimentioning

confidence: 99%

“…However, very few data are available outlining outcomes after this pragmatic approach in MBC [Palmieri et al 2010;Toulmonde et al 2012;Andreupoulou and Sparano, 2013]. In clinical practice, the introduction of liposomal anthracyclines offers an opportunity for anthracycline rechallange in MBC, whereas taxane rechallange may be possible by selecting a different taxane, using an alternative regimen of the same agent or selecting paclitaxel albumin [Palmieri et al 2010]. The first suggestion that nab-paclitaxel does not demonstrate absolute cross-resistance with firstgeneration taxanes is derived from a phase II study on 181 MBC patients, whose disease progressed despite conventional taxane therapy.…”

Section: Clinical Development Of Nab-paclitaxel In Breast Cancer Patimentioning

confidence: 99%

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

2016

View full text Add to dashboard Cite

Abstract:The therapeutic goals in metastatic breast cancer (MBC) remain palliative in nature, aimed at controlling symptoms, improving or maintaining quality of life and prolonging survival. The advent of new drugs and new formulations of standard agents has led to better outcomes in patients with advanced or metastatic disease. These developments have also allowed a tailored therapeutic approach, in which the molecular biology of the tumour, the treatment history, and patient attitudes are taken into account in the decision-making process. Targeting drug delivery to the tumour is a promising mean of increasing the therapeutic index of highly active agents such as the taxanes, and nanoparticle albuminbound paclitaxel (nab-paclitaxel), the first nanotechnology-based drug developed in cancer treatment, is one such advance. Data from randomized trials support the efficacy of singleagent nab-paclitaxel as first-line and further treatment lines in MBC at the registered 3-weekly schedule of 260 mg/m 2 , but emerging evidence suggests its activity as a weekly regimen or combined with other agents in various clinical scenarios. Thus, nab-paclitaxel seems to offer flexibility in terms of dosing schedules, allowing physicians to tailor the dose according to different clinical situations. This paper reviews the clinical trial background for nab-paclitaxel in MBC, focusing on specific 'difficult-to-treat' patient populations, such as taxane-pretreated or elderly women, as well as those with triple-negative, HER2-positive and poor-prognosticfactors disease. Moving beyond evidence-based information, 'real life' available experiences are also discussed with the aim of providing an update for daily clinical practice.

show abstract

“…The interval period between the last medication of prior 5-FU and S-1 monotherapy might also be one of the reasons for it. Actually, retreatment with anthracyclines and taxanes has been reported to be an effective treatment option in metastatic breast cancer [21]. In this study, 83% (5/6) of patients who had completely responded to prior FP regimen achieved CR/SD by S-1 monotherapy.…”

Section: Discussionmentioning

confidence: 63%

S-1 Salvage Chemotherapy for Esophageal Squamous Cell Carcinoma Refractory to the Standard Chemotherapy

Tamaoki¹,

Ezoe²,

Aoyama³

et al. 2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Objective: Fluorouracil, cisplatin, and taxane are widely used in the standard chemotherapy regimens for esophageal squamous cell carcinoma (ESCC). Although S-1 is expected to demonstrate considerable efficacy for ESCC, there is any clinical data. The purpose of this retrospective study was to evaluate the efficacy and safety of S-1 as salvage chemotherapy for ESCC.Methods: From 2007 to 2014, fifteen patients with ESCC refractory or refusal to the standard chemotherapy were treated with S-1 as salvage treatment at the Kyoto University Hospital and their clinical records were reviewed retrospectively. Results:The median age was 70 years old (range: 63-77). A complete response (CR) was achieved in 1 case (7%). A stable disease (SD) and progressive disease (PD) were seen in 9 (60%) and 5 (33%) cases, respectively. After a follow-up duration of 13.9 months, median progression free survival and overall survival was 6.2 and 10.0 months, respectively. One-year survival rate was 33.3%. Toxicities greater than CTCAE grade 3 were observed in 3 of 15 patients (20%). Two patients had grade 3 neutropenia and one patient had grade 3 diarrhea. There was no treatment related death.Conclusions: S-1 salvage chemotherapy could be expected to be an effective and safe treatment option to improve the prognosis of patients with ESCC refractory to the standard chemotherapy.

show abstract

Rechallenging with anthracyclines and taxanes in metastatic breast cancer

Cited by 58 publications

References 76 publications

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

S-1 Salvage Chemotherapy for Esophageal Squamous Cell Carcinoma Refractory to the Standard Chemotherapy

Contact Info

Product

Resources

About